Table 1.
Characteristics of the research cohort* (sample I— cirrhotic patients and sample II—patient with hepatocellular carcinoma (HCC)): gender, vaccination against Covid -19 and death
| Female/Male, % (n) | Vaccination against COVID-19, % (n) Y/N | Death, % (n) Y/N | CTP, % (n) | MELD, % (n) < 12/ > 12 | ||
|---|---|---|---|---|---|---|
| All patients n = 38 | 34.2 (13)/65.8 (25) | 44.7 (17)/55.3 (21) | 39.5 (15)/60.5 (23) | A | 26.3 (10) | 60.5 (23)/39.5 (15) |
| B | 50.0 (19) | |||||
| C | 23.7 (9) | |||||
| Liver cirrhosis (I) n = 31 | 38.7 (12) /61.3 (19) | 48.4 (15)/ 51.6 (16) | 38.7 (12)/61.3 (19) | A | 22.6 (7) | 64.5 (20)/35.5 (11) |
| B | 54.8 (17) | |||||
| C | 22.6 (7) | |||||
| HCC (II) n = 7 | 14.3 (1) /85.7 (6) | 71.4 (5)/28.6 (2) | 42.9 (3)/57.1 (4) | A | 42.8 (3) | 42.9 (3)/57.1 (4) |
| B | 28.6 (2) | |||||
| C | 28.6 (2) | |||||
(CTP) Child-Turcotte-Pugh score, (MELD) Model of End-Stage Liver Disease scales. CTP: class A (well-compensated disease), class B (significant functional compromise), class C (decompensated disease)
*Patients hospitalized between March 15, 2020, and January 31, 2022, in Jerzy Gromkowski Regional Specialist Hospital in Wrocław (Poland)